Objectives: To identify and review methods employed to evaluate medication adherence in studies of oral antineoplastic agents, with particular interest in the opportunities and challenges associated with medication event monitoring systems (MEMS) implemented in observational studies. MethOds: A targeted literature review was conducted to identify studies that have measured adherence with antineoplastic agents. Our review included studies that were published between January 1990 and May 2014. Key data abstracted from each study included patient characteristics, study design and duration, cancer type, treatment, and adherence methodology and results. Based on preliminary results, a second targeted review was conducted to evaluate the literature on the risk of the Hawthorne effect in observational studies utilizing MEMS in any therapeutic area. Results: We identified 69 studies that evaluated adherence to oral chemotherapy; 6 studies were interventional and excluded from further review. Of the remaining 63 studies, 28 (44%) were prospective, 25 (40%) were retrospective, and 10 (16%) were cross-sectional. A total of 15 studies used MEMS to evaluate medication adherence. Among observational studies that utilized MEMS and evaluated the Hawthorne effect (n= 3), mixed results were observed. In two studies, patients reported their behavior was affected by their awareness of being evaluated. This was demonstrated by a significant decrease in adherence between months 1-3 in one study but not measured in the second. The third study showed no change in adherence scores over time and concluded there was no Hawthorne effect. Potential ways to minimize the Hawthorne effect include: study duration > 3 months, blinding patients and physicians to results of MEMS downloads, and use of a patient-completed 'debriefing form' to assess behavior modifications. cOnclusiOns: MEMS have been utilized in observational studies evaluating oral antineoplastic agents. The Hawthorne effect may be present with MEMS caps, but can be minimized and is not prohibitive to study conduct.
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PCn178 a SySTeMaTiC review Of heaLTh STaTe uTiLiTy vaLueS fOr advanCed Ovarian CanCer
Al-Dakkak I. 1 , Borrill J. 2 , Murphy E. 1 , Posnett J. 1 , Zhang Y. 1 1 PAREXEL International, London, UK, 2 AstraZeneca, Macclesfield, UK Objectives: Identifying appropriate utility values to inform cost-effectiveness analysis is a common problem. The aim of this study was to review health-state utility values (HSUVs) for patients with advanced ovarian cancer and make recommendations about their use in the economic evaluation of a targeted maintenance therapy for platinum-sensitive recurrent (PSR) ovarian cancer. MethOds: A systematic search of Embase ® , MEDLINE ® , and MEDLINE ® in Process was conducted in June 2013 for studies reporting direct (standard gamble (SG) or time trade off (TTO)) or indirect (EQ-5D, SF-6D, or HUI-3) utility values for patients with advanced ovarian cancer. HTA agency websites were also searched. Study design, country, HSUV elicitation method, health state (HS) description, and who valued the HS were extracted. Mean (SD) utility scores, or medians (ranges), if means were unavailable, were recorded for each HS. Results: A total of 10 publications were found, representing five primary sources of utility values. Two were derived from trial-based patient-reported EQ-5D profiles; one derived profiles from patients with ovarian cancer and utility values from a sample of the general population using a SG; two derived HSUVs from a sample of women without cancer using a TTO. These studies reported utilities for 18 different health states. Where comparisons were possible, utility values differed widely: clinical remission 0.83-0.977; progression-free after recurrence 0.50-0.715; progressive disease 0.40-0.725. None of the studies reported values for patients receiving maintenance therapy. cOnclusiOns: There is limited health-state utility data for advanced ovarian cancer and wide variations in sample size, methods of elicitation, populations used to provide utility values, and in health state descriptions. Further research is required to provide robust estimates to populate an economic model for a targeted maintenance therapy for PSR ovarian cancer. Given the limitations of the current evidence base additional methods, such as mapping algorithms should be considered.
PCn179 heaLTh-STaTe uTiLiTy vaLueS in breaST and PrOSTaTe CanCer MeaSured uSing The eQ-5d: a SySTeMaTiC review Of The LiTeraTure
Hughes R. , Mitchell C. R. , Bishop R. S. , Fotheringham I Oxford PharmaGenesis Ltd, Tubney, Oxford, UK Objectives: In cost-effectiveness analyses (CEA), a paucity of health-related quality of life (HRQoL) data often necessitates use of utility values from populations which may be ill-matched with the disease modelled. Use of the most pertinent data increases model precision and the accuracy of CEA. This systematic literature review aimed to identify utility values derived from the EQ-5D in patients with breast cancer (BC) or prostate cancer (PC). MethOds: A systematic search was conducted using Medline, Embase and Cochrane databases. Eligible studies for inclusion comprised those reporting EQ-5D utility values in patients with BC or PC at any stage, undergoing or not receiving treatment. Results: 31 studies reported relevant data (BC, 17; PC, 14) . Utility values for metastatic BC (6 studies) ranged from 0.55-0.75 and were lower for patients receiving palliative chemotherapy (CT) or terminal care (0.51-60), while for stage 0-III disease (9 studies), values ranged from 0.74-0.88. In early-stage BC there was little change during follow-up; for stage II/III BC, rapid and sustained recovery was observed following high-dose (HD) CT and was maintained long-term post-HDCT and following adjuvant CT. Values for metastatic PC (9 studies) ranged from 0.63-0.85 and were lower for patients with bone metastases, worse performance status or undergoing palliative care. For localised PC (2 studies),
Objectives: Skeletal-related events (SREs) defined as pathologic fracture, radiation to bone, surgery to bone and spinal cord compression, are common consequences of bone metastasis. Prior studies have shown that SREs increase the utilization of health care resources, including hospitalizations. We estimated the decrease in hospitalizations when a novel superior therapy is used (denosumab), in substitution of zoledronic acid (zol), to treat patients with bone metastases secondary to breast cancer in Germany. MethOds: An analysis was run for predicting the number of SREs avoided and the reduction in number of hospitalizations attributable to treatment with denosumab. The number of breast cancer patients was collected from a German registry using the International Classification of Disease codes. Epidemiological data were then utilized to derive the number of hospitalizations due to bone metastases. The number of patients treated for SREs prevention was obtained from market research and applied to either treatment. The total number of SREs observed was based in the SREs rates seen in a phase 3 clinical trial. German data from a multinational retrospective chart review was used to quantify the inpatient hospitalization rates and length of stay associated with each type of SRE. Results: Approximately 9,500 patients per year with breast cancer and bone metastases were estimated to be treated with denosumab or zol in Germany. The resulting 2,100 SREs prevented per year led to a reduction of approximately 700 hospitalizations per year. The total number of days per inpatient stay avoided by using denosumab instead of zol was approximately 5,000 per year. cOnclusiOns: The superior efficacy of denosumab compared to zol reduces the disease burden by decreasing the number of SREs and consequently the number of hospitalizations and inpatient days. Since the reimbursement landscape for clinical genomic sequencing is currently unknown, a comprehensive cost calculation reflecting resource utilization across the whole sequencing workflow including costs associated with directed therapy based on molecular profiling results is necessary. These data serve as a starting point toward identifying and valuating resources associated with NGS and serve as a first step toward demystifying reimbursement for clinical genomic sequencing in Pediatric Oncology.
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CLiniCaL iMPLeMenTaTiOn Of genOMiC SeQuenCing in PediaTriC OnCOLOgy: idenTifiCaTiOn and vaLuaTiOn Of reSOurCeS and COSTS aSSOCiaTed wiTh nexT-generaTiOn SeQuenCing
PCn176 aMnOg benefiT aSSeSSMenT fOr OnCOLOgiC and OrPhan drugS in gerMany -iMPLiCaTiOnS fOr PriCe diSCOunTS
Theidel U. , Wahlers K. , Mittendorf T.
Herescon GmbH, Hannover, Germany
Objectives: With the start of AMNOG in 2011, industry is demanded to submit and defend evidence as well as negotiate discounts for new drugs with an additional patient benefit in Germany. The National Association of Statutory Health Insurances (SpiBu) negotiates with a discount on the ex-factory price on top of a mandatory discount. Evaluating final prices, questions arise regarding factors might influence discounts and impact the German market especially for oncologic and orphan drugs. MethOds: A database containing detailed information for all past assessments was used to explore potential impact factors for discounts. Starting with an analysis of background information (discount, areas etc.) descriptive statistics were employed. Furthermore, we analyzed past assessments with respect to: number and size of target population, results of the benefit assessment, change in ex-factory price, magnitude of discount, incorporation of quality of life evidence, and acceptance of comparator therapy among others. Results: Until June 2014 24 price negotiations were completed for oncologic and/or orphan drugs (neoplasm: 16, orphan drugs [w/o oncologics]: 8). It is inconclusive, if the scale of benefit influences the price discount. An additional benefit was granted by the G-BA in 21 of 24 cases. The magnitude of the discount tends to be higher in groups with smaller target populations and quality of life evidence has no influence on the negotiated discount. Discount rates might be smaller if the companies do not deviate from recommendations given by the G-BA. In addition to discounts, some companies needed to lower their ex-factory price. cOnclusiOns: Whereas binding and strict rules are in place for the benefit assessment itself, there is no algorithm for prediction of levels of price discounts. To decrease uncertainty for scenario planning a set algorithm or procedure would be preferable. Further research is needed to evaluate those criteria.
